{"id":"nct:NCT04338321","kind":"trial","title":"A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder","authors":["Janssen-Cilag International NV"],"author_count":1,"year":2020,"published":"2020-04-08","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT04338321","source_url":"https://clinicaltrials.gov/study/NCT04338321","archive_url":"https://space-kitty.com/papers/nct:NCT04338321","updated":"2025-04-29","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission in participants who have treatment-resistant major depressive disorder (MDD) with a current moderate to severe depressive episode.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Depressive Disorder, Major"],"details":{"acronym":"ESCAPE-TRD","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":676,"sponsor":"Janssen-Cilag International NV","conditions":["Depressive Disorder, Major"],"interventions":["DRUG: Esketamine 28 mg","DRUG: Esketamine 56 mg","DRUG: Esketamine 84 mg","DRUG: Quetiapine XR 50 mg","DRUG: Quetiapine XR 100 mg","DRUG: Quetiapine XR 150 mg","DRUG: SSRI/SNRI"],"start_date":"2020-08-21","start_date_type":"ACTUAL","primary_completion_date":"2022-01-20","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"psychiatric-therapeutics","name":"Novel Psychiatric Therapeutics","domain_slug":"neuroscience"}],"cited_in_dossiers":[]}